KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Current Leases (2019 - 2025)

Novartis Ag (NVS) has disclosed Current Leases for 7 consecutive years, with $263.0 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 11.91% to $263.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $263.0 million through Dec 2025, up 11.91% year-over-year, with the annual reading at $263.0 million for FY2025, 11.91% up from the prior year.
  • Current Leases hit $263.0 million in Q4 2025 for Novartis Ag, up from $235.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $275.0 million in Q4 2021 to a low of $230.0 million in Q4 2023.
  • Historically, Current Leases has averaged $250.8 million across 5 years, with a median of $251.0 million in 2022.
  • Biggest five-year swings in Current Leases: decreased 8.73% in 2022 and later grew 11.91% in 2025.
  • Year by year, Current Leases stood at $275.0 million in 2021, then fell by 8.73% to $251.0 million in 2022, then fell by 8.37% to $230.0 million in 2023, then grew by 2.17% to $235.0 million in 2024, then increased by 11.91% to $263.0 million in 2025.
  • Business Quant data shows Current Leases for NVS at $263.0 million in Q4 2025, $235.0 million in Q4 2024, and $230.0 million in Q4 2023.